Selinexor, Venetoclax, and Decitabine for Refractory Myelodysplastic Syndrome
Author Information
Author(s): Xiao Yunshuo, Yang Kun, Huang Qiuying, Wei Changqing, Wei Manlv, Geng Zhili, Wu Hui, Zhou Tianhong, Yin Xialoin, Zhou Yali
Primary Institution: The 923rd Hospital of the Joint Logistics Support Force of the People’s Liberation Army, Nanning, China
Hypothesis
Can the combination of selinexor, venetoclax, and decitabine effectively treat patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents?
Conclusion
The combination therapy of selinexor, venetoclax, and decitabine can achieve complete remission and significant reductions in spleen size in patients with refractory myelodysplastic syndrome.
Supporting Evidence
- All three patients achieved complete remission after treatment.
- The treatment regimen was safe and effective.
- Significant reductions in spleen size were observed in all patients.
- Patients successfully underwent hematopoietic stem cell transplantation.
Takeaway
This study shows that a new combination of three medicines can help people with a tough blood disease get better and even prepare them for a special treatment called a stem cell transplant.
Methodology
Three case reports of patients with refractory myelodysplastic syndrome treated with a combination of selinexor, venetoclax, and decitabine.
Limitations
The study is based on only three cases, lacking control groups and randomization, which limits generalizability.
Participant Demographics
Three patients: 2 females aged 35 and 39, and 1 male aged 48.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website